Platelet protein kinase C levels in Alzheimer's disease.
Alzheimer's disease (AD) has been suggested to be a systemic disease, and signal transduction abnormalities have been reported in non-neuronal AD cells. We have previously quantified the protein kinase C (PKC) subtypes in AD and control brains using a two-site enzyme immunoassay (EIA), and have shown that type II PKC levels were significantly reduced in the temporal cortex of AD patients. In this study, we used this EIA to assess the platelet levels of type II PKC in age-matched groups of AD patients and normal controls. The cytosolic level of type II PKC was significantly higher in AD platelets than in control platelets but was unchanged in the membranous fraction. Platelet proteins showed no differences between the AD and control groups. Therefore, the type II PKC content of the cytosolic fraction was increased in AD platelets. These results suggest that type II PKC may be altered in both the brain and platelets of AD patients and support the hypothesis that AD is a systemic disease.
Matsushima
H
H
Department of Neurology, Faculty of Medicine, Kyoto University, Japan.
Shimohama
S
S
Tanaka
S
S
Taniguchi
T
T
Hagiwara
M
M
Hidaka
H
H
Kimura
J
J
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000201:enzymology*; D001792:Blood Platelets / Q000201:enzymology*; D001921:Brain / Q000201:enzymology; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D016555:Matched-Pair Analysis; D011493:Protein Kinase C / Q000097:blood* / Q000145:classification
D011493:Protein Kinase C